Winona publishes a guide walking women through what its telehealth menopause care actually costs, who qualifies, and what to expect month to month after starting treatment
Chicago, Illinois— January 3, 2026 — (Access Newswire) — Winona, a physician-led telehealth company focused on menopause and perimenopause care, published a guide today that addresses the most common questions women ask before starting hormone therapy: what it costs, who's eligible, and what a realistic treatment timeline looks like.
Winona's care model is made up of three entities, which is standard practice for telehealth services. Winona, Inc. operates the secure technology platform and intake process. Winona Medical Group, made up of independently licensed physicians, reviews each patient's medical history and makes all clinical decisions, including whether hormone therapy is appropriate. The third entity is their 503A-regulated compounding partner pharmacies that fill the prescriptions. Winona cannot guarantee that any individual will receive a prescription, since that decision rests entirely with the evaluating physician.
The intake process starts with a 10 to 15 minute online questionnaire covering medical history, current symptoms, menstrual history, and individual treatment goals. A licensed, board-certified physician then reviews the information, typically returning a personalized treatment recommendation within about 24 hours. If the patient is determined to be a suitable candidate for hormone therapy, medications are shipped directly to their home, usually arriving within about a week.
Winona's published pricing shows that most combination therapies cost approximately $89 to $238 per month, depending on the formulations prescribed. Ongoing messaging with a physician is included in the cost rather than billed separately. Winona does not accept insurance directly, although some patients may be able to submit receipts to their own plan for reimbursement. The platform also accepts HSA and FSA payments at checkout.
The guide is also clear about who hormone therapy isn't appropriate for. Following guidance from the Menopause Society and the American College of Obstetricians and Gynecologists (ACOG), Winona's intake screens for treatment contraindications. This includes a personal history of breast, ovarian, or endometrial cancer, prior blood clots or stroke, active liver disease, unexplained vaginal bleeding, or suspected pregnancy. Because hormone levels fluctuate unpredictably during perimenopause, Winona's physicians evaluate and adjust treatment based on reported symptoms rather than standard lab testing, which can only provide a snapshot of what hormones are doing at that moment.
For women with questions about the treatment timeline, Winona outlines how research shows that patients can generally expect initial reductions in hot flash frequency and improved sleep within the first two to four weeks. More substantial improvement in hot flashes, mood, and vaginal symptoms often occurs around three months, with individual results varying by age, health history, and consistency of use.
The guide closes by comparing the benefits and limitations of telehealth with in-person menopause care. Telehealth removes geographic and scheduling barriers but doesn't include a physical exam. In-person care offers hands-on evaluation but often comes with long specialist wait times and higher consultation costs. Winona encourages women to weigh both options based on medical history, healthcare access, and insurance coverage.
Women can check state availability, review current pricing, and start the intake process at https://bywinona.com.
*This release is intended for general educational purposes. It is not medical advice and does not replace an individualized evaluation by a licensed clinician.*